Providing Veterans Essential Medications Act

1) WHAT HAPPENED: HR1970 was introduced March 10, 2025 by Rep. Miller-Meeks (R-IA) with 48 cosponsors. It was referred to the Subcommittee on Health on March 27, 2025. The bill is in its earliest legislative stage — committee mark-up has not occurred, and no companion Senate bill exists. 2) MONEY TRAIL: The bill authorizes NO specific dollar amount. It amends 38 U.S.C. §1745(a)(3) to require the VA to either reimburse State homes for high-cost medications (defined as drugs whose monthly wholesale price exceeds 8.5% of the per-diem payment plus 3% transaction fee) or furnish them directly. Because no funding authorization exists, full implementation depends on VA reallocating existing appropriations or passing a separate appropriations bill. 3) WINNERS/LOSERS: Pharmacy distributors with exposure to long-term care pharmacy and VA formularies — CVS (via Omnicare and Caremark) and Cardinal Health — stand to benefit from guaranteed payment streams for high-cost veteran medications. However, the narrow scope (only State home nursing care veterans) limits total addressable volume. Pure-play long-term care pharmacy companies are absent from public markets (Omnicare is now part of CVS), so impact accrues to diversified distributors. 4) REAL MARKET DATA: Over the past 30 days, CVS has rallied 16.08% to $83.37, near its 52-week high of $85.15, driven by broader healthcare sector dynamics and potential PBM reform outcomes, not this early-stage VA bill. CAH has declined 10.26% to $189.63, well off its $233.60 high, amid distributor sector headwinds. The divergence between CVS and CAH reflects company-specific factors rather than HR1970. 5) TIMELINE: The bill must pass House Veterans' Affairs committee, then the full House, then the Senate (no companion bill exists), then be reconciled. For a low-priority authorization bill with no funding, 12-18 months to passage is optimistic. Most such bills die in committee.